Irhythm Technologies ( (IRTC) ) has released its Q1 earnings. Here is a breakdown of the information Irhythm Technologies presented to its investors.
iRhythm Technologies, Inc. is a digital healthcare company specializing in wearable biosensors and data analytics to detect, predict, and prevent diseases, primarily focusing on cardiac arrhythmias. In the first quarter of 2025, iRhythm Technologies reported a revenue increase of 20.3% year-over-year, reaching $158.7 million, with a gross margin improvement to 68.8%. The company highlighted strong demand for its Zio services in the U.S. and U.K., and expanded its global presence with the launch of the Zio monitor in Japan. Key financial metrics showed a net loss of $30.7 million, a significant improvement from the previous year, attributed to revenue growth and operational efficiencies. Looking ahead, iRhythm projects its 2025 revenue to be between $690 million and $700 million, with an adjusted EBITDA margin of 7.5% to 8.5%, indicating a positive outlook for continued growth and market expansion.